SLC39A1 contributes to gemcitabine resistance of pancreatic ductal adenocarcinoma by activating AMPK signaling

• Main Authors: Hao Yu (Author), Xiaoping Mei (Author), Xueming Zhang (Author), Neng Qian (Author), Qingjiang Yu (Author), Hongkun Zhou (Author)
• Format: Book
• Published: Bangladesh Pharmacological Society, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gemcitabine is a common first-line chemotherapy agent, but gemcitabine resistance is a clinical challenge for pancreatic ductal adenocarcinoma patients. Solute carrier 39A1 (SLCA39A1) as a zinc regulator presents a crucial function in the modulation of malignancy progression. Here, the impact of SLC...